NTRK3 and neoplasm: Additionally, objective responses were achieved with other MMTs, including vemurafenib/cobimetinib in BRAF V600E-mutant SDC (n = 3), larotrectinib in secretory carcinoma with ETV6::NTRK3 gene fusions (n = 2), and ipilimumab/nivolumab in mucoepidermoid carcinoma with high tumour mutational burden (n = 1).<h4>Conclusions</h4>Comprehensive molecular testing in SGC may allow access to MMT, with a subset of patients experiencing clinical benefit from this strategy.